Literature DB >> 1975484

Can early administration of neostigmine, in single or repeated doses, alter the course of neuromuscular recovery from a vecuronium-induced neuromuscular blockade?

T T Magorian1, D P Lynam, J E Caldwell, R D Miller.   

Abstract

The authors sought to determine whether neostigmine, given at a time when no response to peripheral nerve stimulation could be elicited, hastened recovery from a vecuronium-induced neuromuscular blockade (NMB). The effect of neostigmine (70 micrograms/kg) in antagonizing a profound (no-twitch) vecuronium-induced (0.1 mg/kg) NMB in 40 healthy patients was studied. Patients were randomly assigned to one of four groups specifying the sequence of neostigmine administration. Fifteen minutes after the administration of vecuronium, when there was no detectable twitch response, each patient received either neostigmine (70 micrograms/kg) with glycopyrrolate (15 micrograms/kg) or an equivalent volume of normal saline (placebo). When T1 (the first response in the train-of-four [TOF] sequence) recovered to 10% of control, patients again received either neostigmine with glycopyrrolate in the same doses as before or the placebo. The following variables were measured: times from vecuronium injection until T1 recovered to 10% (t [10]) and 90% (t [90]) of control, and time until the TOF ratio was equal to 75% (t [TOF75]). Mean values of t (90) and t (TOF75) were shorter (54.7-75.2 min and 60.4-79.5 min, respectively) for the three groups who received neostigmine as compared with patients who received two doses of placebo (104.3 and 122.6 min, respectively). There were no differences in the t (90) and t (TOF75) values among the three groups who received neostigmine.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1975484     DOI: 10.1097/00000542-199009000-00008

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  10 in total

1.  Optimum time for neostigmine reversal of atracurium-induced neuromuscular blockade.

Authors:  H Kirkegaard-Nielsen; H S Helbo-Hansen; P Lindholm; I K Severinsen; H S Pedersen; E W Jensen
Journal:  Can J Anaesth       Date:  1996-09       Impact factor: 5.063

Review 2.  [Deep neuromuscular blockade : Benefits and risks].

Authors:  C Unterbuchner; M Blobner
Journal:  Anaesthesist       Date:  2018-03       Impact factor: 1.041

3.  Comparison of tactile and mechanomyographical assessment of response to double burst and train-of-four stimulation during moderate and profound neuromuscular blockade.

Authors:  H Kirkegaard-Nielsen; H S Helbo-Hansen; I K Severinsen; P Lindholm; H S Pedersen; M B Schmidt
Journal:  Can J Anaesth       Date:  1995-01       Impact factor: 5.063

4.  Edrophonium priming alters the course of neuromuscular recovery from a pipecuronium neuromuscular blockade.

Authors:  M Naguib; M Abdulatif
Journal:  Can J Anaesth       Date:  1991-09       Impact factor: 5.063

Review 5.  [Algorithm-based preventive strategies for avoidance of residual neuromuscular blocks].

Authors:  C Unterbuchner; K Ehehalt; B Graf
Journal:  Anaesthesist       Date:  2019-11       Impact factor: 1.041

6.  Reversal of profound vecuronium-induced neuromuscular block under sevoflurane anesthesia: sugammadex versus neostigmine.

Authors:  Hendrikus Jm Lemmens; Mohammad I El-Orbany; James Berry; Jovino Ben Morte; Gavin Martin
Journal:  BMC Anesthesiol       Date:  2010-09-01       Impact factor: 2.217

7.  Comparison of neostigmine induced reversal of vecuronium in normal weight, overweight and obese female patients.

Authors:  Shilpa Bhimasen Joshi; Ks Vasudeva Upadhyaya; M Manjuladevi
Journal:  Indian J Anaesth       Date:  2015-03

8.  Recovery of muscle function after deep neuromuscular block by means of diaphragm ultrasonography and adductor of pollicis acceleromyography with comparison of neostigmine vs. sugammadex as reversal drugs: study protocol for a randomized controlled trial.

Authors:  Iacopo Cappellini; Fabio Picciafuochi; Daniele Ostento; Ginevra Danti; Angelo Raffaele De Gaudio; Chiara Adembri
Journal:  Trials       Date:  2018-02-21       Impact factor: 2.279

Review 9.  Is lower-dose sugammadex a cost-saving strategy for reversal of deep neuromuscular block? Facts and fiction.

Authors:  Hans D de Boer; Ricardo V Carlos; Sorin J Brull
Journal:  BMC Anesthesiol       Date:  2018-11-06       Impact factor: 2.217

10.  The efficacy and safety of sugammadex for reversing postoperative residual neuromuscular blockade in pediatric patients: A systematic review.

Authors:  Guangyu Liu; Rui Wang; Yanhong Yan; Long Fan; Jixiu Xue; Tianlong Wang
Journal:  Sci Rep       Date:  2017-07-18       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.